Table I.

Characteristics of research subjects by race and prostate cancer aggressiveness

	European American n = 1,079					African American n = 1,023
Characteristics	High aggressive CaP (n=164 )		Low/intermediate aggressive CaP (n=915 )			High aggressive CaP (n=206 )		Low/intermediate aggressive CaP (n=817)
	Mean (SD)		Mean (SD)		P value‡	Mean (SD)		Mean (SD)		P value‡
Age, years	67 (8)		64 (8)		<0.0001	64 (8)		62 (8)		0.004
Energy Intake, kcals/day	2339 (952)		2320 (866)		0.80	2800 (1232)		2593 (1146)		0.02
Dietary Fat Intake, grams/day	94 (42)		91 (39)		0.31	104(52)		95(485)		0.02
Body Mass Index (BMI), kg/m2	30 (5)		29 (5)		0.0006	30 (7)		29 (55)		0.16
	N	%	N	%		N	%	N	%
Study Site
North Carolina	73	45	448	49	0.29	92	45	386	47	0.51
Louisiana	91	55	467	51		114	55	431	53
Family History of Prostate Cancer
No affected 1st degree relative	136	83	696	76	0.05	157	76	606	74	0.55
At least 1 affected 1st degree relative	28	17	219	24		49	24	211	26
PSA Screening History
0 screenings	40	24	153	17	0.06	120	58	307	38	<0.0001
1–7 screenings	68	42	405	44		53	26	338	41
> 7 screenings	56	34	357	39		33	16	172	21
Comorbidities
0	84	51	503	55	0.05	88	43	382	47	0.39
1	31	19	214	23		53	26	216	26
2	29	18	98	11		36	17	106	13
≥ 3	20	12	100	11		27	14	109	14
Started CaP treatment at start of study
No	11	7	99	11	0.007	20	10	112	14	0.20
Yes	146	89	720	79		163	79	599	73
Unknown	7	4	96	10		23	11	106	13
Education
Less than high school education	27	17	81	9	0.005	85	41	243	30	0.001
High school graduate/ some college	79	48	432	47		102	50	438	54
College graduate	58	35	402	44		19	9	135	16
Income Level
≤ $20, 000	24	15	78	9	0.11	82	40	234	29	0.0005
$20,001 – $40,000	33	20	184	20		52	25	212	26
$40,001 – $70,000	38	23	217	24		24	12	171	21
>$70,000	53	32	359	39		22	11	130	16
Unknown	16	10	77	8		26	12	70	8
Smoking Status
Never	59	36	330	36	0.76	40	19	276	34	<0.001
Former smoker	87	53	501	55		107	52	390	48
Current smoker	18	11	84	9		59	29	151	18
NSAID Use
No	56	34	305	33	0.85	84	41	364	45	0.33
Yes	108	66	608	67		120	59	446	55

Prostate cancer aggressiveness defined by a combination of Gleason sum, clinical stage, and PSA level at diagnosis and classified as follows: high aggressive (Gleason sum ≥8 or PSA >20ng/ml or Gleason sum ≥7 AND clinical stage T3 -T4); low/intermediate aggressive: all other cases.

Abbreviations: CaP – Prostate Cancer; NSAIDs – Nonsteroidal anti-inflammatory drugs; PSA – prostate-specific antigen; SD – Standard deviation.

^‡Test for differences between high and low/intermediate CaP performed using Student t-test for continuous variables and chi-square tests for categorical variables.